GlassScriptPhysician profile
Lauren Worth
NPI 1457976185
$3,457.01
in general payments reported to CMS, 2019-2025
23 companies · $2,286 in 2025
The $2,286 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $20.97 · 2024: $1,025 · 2025: $2,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,144 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,144.03 |
| Education | $187.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $596.03 | 2024-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $533.23 | 2022-2025 | Haegarda, Hizentra, Andembry |
| Genzyme Corporation | $381.33 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $353.42 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $333.50 | 2024-2025 | Takhzyro, Glassia, Aralast |
| Biocryst US Sales Co., LLC | $203.30 | 2024-2025 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $187.98 | 2025 | |
| Genentech USA, INC. | $106.32 | 2025 | Xolair |
| Octapharma USA, INC. | $105.72 | 2025 | Panzyga, Octagam Immune Globulin (Human) |
| Pfizer INC. | $97.88 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $89.18 | 2024-2025 | Dupixent |
| Amgen INC. | $75.42 | 2024 | Tezspire |
| Invivyd INC | $65.14 | 2024-2025 | Pemgarda |
| Pharming Healthcare, INC. | $57.28 | 2025 | Ruconest |
| Glaxosmithkline, LLC. | $55.19 | 2025 | Nucala |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $41.79 | 2024 | Auvi-Q |
| Phadia US INC. | $34.97 | 2024-2025 | Immunocap |
| Lilly USA, LLC | $30.49 | 2024-2025 | Ebglyss |
| Verona Pharma, INC. | $26.32 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $24.87 | 2024 | Gamunex-C |
| Blueprint Medicines Corporation | $21.95 | 2025 | Ayvakit |
| Tersera Therapeutics LLC | $21.02 | 2024 | Quzyttir |
| X4 Pharmaceuticals, INC. | $14.68 | 2024 | Xolremdi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Worth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.